Unlike LDL uptake, Lp(a) uptake is not altered by PCSK9 or PCSK9 inhibition in primary human hepatocytes and in primary dermal fibroblasts isolated from familial hypercholesterolemic and nonfamilial hypercholesterolemic patients. Lp(a) uptake is occurring in the absence of a functional LDL receptor and is not affected by LDL receptor blockade with monoclonal antibodies. Lp(a) cellular binding and whole particle uptake are not altered by PCSK9. The secretion of Lp(a) from primary human hepatocytes is enhanced by PCSK9, an effect that is blunted by PCSK9 inhibition with alirocumab.
SUMMARY
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and measured Lp(a) secretion from human hepatocytes. They found that Lp(a) cellular uptake occurred in a low-density lipoprotein receptor-independent manner. Neither PCSK9 nor alirocumab altered Lp(a) internalization. By contrast, the secretion of apolipoprotein (a) from human hepatocytes was sharply increased by PCSK9, an effect that was reversed by alirocumab. They propose that PCSK9 does not significantly modulate Lp(a) catabolism, but rather enhances the secretion of Lp(a) from liver cells. Both statins and anti-PCSK9 mAbs act by increasing the abundance of LDLR at the surface of hepatocytes, promoting an accelerated clearance of circulating low-density lipoprotein (LDL) particles, thus lowering LDL-C levels (4, 5) . But, unlike statins (6) , anti-PCSK9 mAbs also promote an unexplained 25% to 30% reduction in circulating lipoprotein (a) [Lp(a)] levels (1, 2, 7) .
There is strong epidemiological evidence that Lp(a) is a highly atherogenic lipoprotein (8) , because elevated Lp(a) levels are independently and significantly associated with cardiovascular disease (6, 9, 10) . Lp(a) consists of a unique protein homologous to plasminogen, apolipoprotein (apo) (a) [apo(a)], that is covalently tethered to the apolipoprotein B100 [apoB100] moiety of an LDL particle by a unique disulfide bond (11) . Apo(a) is a high-molecular-weight glycoprotein (w300 to 800 kDa), expressed exclusively by the liver, that contains from 3 to more than 40 identical Kringle IV 2 domains.
A strong inverse relationship exists between the apo(a) isoform size and Lp(a) plasma concentration in humans (12) . Circulating Lp(a) concentrations appear to be primarily controlled by synthesis rather than catabolism (12) . The molecular and cellular pathways governing apo(a)/Lp(a) hepatic production and Lp(a) cellular uptake and degradation are not well understood (13) . The potential role of the LDLR in Lp(a) clearance remains controversial (8, 14) .
There is currently a clear need to understand how, unlike statins, anti-PCSK9 mAbs reduce the circulating levels of Lp(a) in patients. This could result from an enhanced clearance and/or a reduced production of Lp(a). To answer this question, we have investigated the role of PCSK9 and of the LDLR in mediating Lp(a) cellular uptake. We also investigated the effects of PCSK9 and of the anti-PCSK9 monoclonal antibody alirocumab on Lp(a) secretion from primary human hepatocytes. We report that Lp(a) production from hepatocytes is enhanced by PCSK9 and blunted by alirocumab, whereas neither PCSK9 nor the LDLR seem to significantly modulate Lp(a) catabolism. Table 1) treated with mevastatin with or without PCSK9 in the presence or absence of alirocumab. We verified that LDL cellular uptake correlated with LDLR cell surface expression levels (5, 15) . Maximal fluorescent LDL internalization was observed in control fibroblasts, followed by HeFH fibroblasts, and then receptordefective and receptor-negative HoFH fibroblasts ( Figure 1A) . PCSK9 reduced whereas alirocumab restored LDL uptake in all fibroblast lines, except for those receptor-negative HoFH fibroblasts totally lacking LDLR function ( Figures 1A and 1B) . Fluorescent LDL uptake was reduced by the addition of 20-fold excess unlabeled LDL to the culture medium ( Figure 1C) . Figure 3A) . We verified the functionality of the LDLR in primary human hepatocytes by adding an antibody targeting the extracellular domain of the LDLR to the culture medium. Blocking the LDLR with this antibody reduced the cellular uptake of fluorescent LDL ( Figure 3A) . After stringent washing, PCSK9 reduced fluorescent LDL endocytosis but had no effect on fluorescent Lp(a) endocytosis (Supplemental Figure 3 ). We confirmed that native Lp(a) (i.e., unlabeled) and fluorescently labeled Lp(a) were equally internalized by primary hepatocytes by measuring intracellular apo(a) contents. Furthermore, we demonstrated that PCSK9 had no effect on native Lp(a) uptake by primary hepatocytes (Supplemental Figure 4) . The integrity of Lp(a) Figures 4A and 4B) . The effects of PCSK9 were similar in hepatocytes isolated from both donors.
DISCUSSION
In this work, we investigated the mechanisms by which anti-PCSK9 mAbs reduce circulating Lp(a) levels in humans. We showed that Lp(a) cellular uptake was not (5) . In line with our results, Reblin et al. (18) showed that the specific uptake of I 125 -Lp(a) (but not that of I 125 -LDL) was similar in wild-type and LDLRknockout mouse embryonic fibroblasts. Furthermore, Niemeier et al. (19) found that Lp(a) was a very weak ligand for the LDLR in BIAcore studies. Our results are also in agreement with clinical studies showing that PCSK9 inhibition (with evolocumab) promoted significant reductions in both circulating LDL-C (À24%) and Lp(a) (À19%) in 6 receptor-defective HoFH patients and reduced Lp(a) (À18%), but not LDL-C (þ15%) levels in 2 receptor-negative HoFH patients (20) . Finally, our results are concordant with the previously published observations that upregulating LDLR expression even with the most potent statins does not reduce Lp(a) in humans (6) , and that Lp(a) plasma clearance occurs at similar catabolic rates in non-FH, HeFH, and HoFH patients (12, 21) .
In this study, we also performed Lp(a) and LDL uptake experiments in primary hepatocytes obtained from 2 donors. In line with our findings in fibroblasts, we showed that PCSK9 reduces LDLR expression and function (i.e., LDL uptake) without altering Lp(a) cellular uptake. Blocking LDLR function with an antibody yielded similar results. In contrast to our findings, a recent study found that PCSK9 reduced the internalization of Lp(a) in HepG2 cells (14) . We are uncertain how to explain the discrepancies between the 2 studies. One possible explanation would be that we used primary human hepatocytes, whereas Romagnuolo et al. (14) used a hepatoma cell line.
However, Romagnuolo et al. (14) found that PCSK9 reduced the uptake of Lp(a) in human dermal fibroblasts expressing the LDLR. Because Romagnuolo et al. (14) observed that recombinant apo(a) uptake, unlike Lp(a) particle uptake, was not altered by PCSK9 and/or LDLR expression in dermal fibroblasts, we confirmed in the present study that apo(a) had not detached from Lp(a) particles during our incubation process (Supplemental Figure 5) . A less likely explanation for the discrepancies between the 2 studies is that there were differences in apo(a) isoforms, as we used Lp(a) with apo(a) isoforms containing 9 to 19 Kringle IV 2 domains, whereas Romagnuolo et al. (14) used apo(a) isoforms containing 7 to 8 Kringle IV 2 domains (14) . A third possible explanation for the discrepancies between the 2 studies is that we used Because we did not observe any effect of PCSK9 on Lp(a) cellular uptake by human hepatocytes, we tested whether PCSK9 might modulate Lp(a) secretion from these cells. We showed a PCSK9 dosedependent increase in both apoB and apo(a) (free and lipidated) in the culture medium, an effect that PCSK9 Enhances Lp(a) Secretion But Not its Catabolism
